CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 88 enrolled
Drug / intervention
hI-con1 +2 morebiological
Likely dose
hI-con1 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02358889
NCT02358889Phase 2Completed
CompareCT.gov

A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Iconic Therapeutics, Inc.·interventional·Posted Feb 9, 2015·Updated Sep 24, 2020

In Brief

A Phase 2 clinical trial evaluating hI-con1, ranibizumab, and 1 other intervention for Choroidal Neovascularization and Age-related Macular Degeneration. Completed, enrolled 88 participants across 48 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoroidal Neovascularization, Age-related Macular Degeneration
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 9, 2015
Enrollment StartFeb 1, 2015
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.4 years ago

Interventions

hI-con1biological

Intravitreal injection of hI-con1 0.3 mg

ranibizumabbiological

Intravitreal injection of ranibizumab 0.5 mg

Sham injectionother

No injection is given, a needleless syringe is used to mimic an injection.